Hepatocellular carcinoma (HCC) is the most common primary liver malignant neoplasia. HCC is characterized by a poor prognosis. The need to find new molecular markers for its diagnosis and prognosis has led to a progressive increase in the number of scientific studies on this topic. MicroRNAs (miRNAs) are small noncoding RNA that play a role in almost all main cellular pathways. miRNAs are involved in the regulation of expression of the major tumor-related genes in carcinogenesis, acting as oncogenes or tumor suppressor genes. The aim of this review was to identify papers published in 2017 investigating the role of miRNAs in HCC tumorigenesis. miRNAs were classified according to their role in the main molecular pathways involved in HCC tumorigenesis: (1) (3) JAK/STAT; (4) apoptosis; and (5) MAPK. The role of miRNAs in prognosis/response prediction was taken into consideration. Bearing in mind that the analysis of miRNAs in serum and other body fluids would be crucial for clinical management, the role of circulating miRNAs in HCC patients was also investigated. The most represented miRNA-regulated pathway in HCC is mTOR, but apoptosis, Wnt, JAK/STAT or MAPK pathways are also influenced by miRNA expression levels. These miRNAs could thus be used in clinical practice as diagnostic, prognostic or therapeutic targets for HCC treatment.
INTRODUCTION
Hepatocellular carcinoma (HCC), the most common primary liver malignant neoplasia, is a very diffuse mali gnancy, with variable incidence according to geography, and represents the fifth cause of cancer-related death worldwide [1, 2] . Generally, HCC is characterized by a poor prognosis, mainly due to the limited treatment choices [3] : prognosis after surgery including liver transplantation depends on the tumor stage, the asso ciation with cirrhosis and on liver function [4] . Histology can be of little help in predicting the response to surgery, since the classic wellestablished histological features of HCC are seldom evaluable on liver needle biopsy: microvascular invasion (MVI) is rarely seen on biopsy, and tumor grade and architecture are too heterogeneous in HCC to be assessed on the basis of small sampling. Up to now, the most reliable prognostic markers after surgery are clinical and surgical, e.g., the complete resection of the lesion, liver function tests, and alphafetoprotein [5] . For liver transplantation, the inclusion within the Milan criteria remains a cornerstone for the good outcome of the recipients [6] . As for the systemic therapy for HCC, no serious options have been available until 2007, when the neoangiogenesis agent Sorafenib was introduced. Sorafenib gave one more chance to those patients with highstage and MVIpositive HCC, not suitable for surgery [7, 8] . Again, no predictive tests are available to assess which patients will benefit most from Sorafenib therapy.
The need to find new tissue and/or serum markers for HCC diagnosis and prognosis progressively increased the number of studies on the molecular mechanism behind liver carcinogenesis. The issue, however, still remains tangled, due to the high heterogeneity of HCC (not only in phenotype), and to the complex multistep carcinogenesis occurring differently in cirrhotic and non cirrhotic livers [2] . MicroRNAs (miRNAs) are small noncoding RNA (2025 nucleotides) that play a role in almost all main cellular pathways [9] . miRNAs contribute to a variety of physiological and pathological events, including several types of tumors [1015] . Thus, miRNAs are involved in the regulation of expression of the major tumorrelated genes in carcinogenesis, acting as oncogenes or tumor suppressor genes [16] . The aim of this review was to identify papers published in the last 12 mo (from January 2017 to December 2017), investigating the possible role of miRNAs in HCC tumorigenesis. miRNAs were classified according to their role in the main molecular pathways involved in HCC: (1) mTOR; (2) Wnt; (3) JAK/STAT; (4) apoptosis; and (5) MAPK. Moreover, the possible role of miRNAs in prognosis/response prediction and the level of circulating miRNAs in HCC patients were also investigated.
mIRNAs IN HCC mOLECULAR
PATHWAYs mTOR pathway mTOR (mammalian target of rapamycin) is a well con served serinethreonine kinase that plays a fundamental role in the signaling network that controls growth and cell metabolism. mTOR is the physical target of rapamycin. mTOR exists in two different multiprotein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is composed of five components: mTOR, Raptor, PRAS40, GβL, and DEPTOR [17] . mTORC1 is directly inhibited by rapamycin but, at the same time, it is modulated by genotoxic stress, growth factors, oxygen and energy status, resulting in modulation of cell growth and proliferation [18] . These inputs indirectly regulate mTORC1 by controlling the activation status of TSC1TSC2. For example, growth factors block TSC1 TSC2 and mTORC1 is consequently activated. On the contrary, energy deficit, genotoxic stress or oxygen deprivation are positive signals on TSC1TSC2, which inhibit mTORC1. Activated mTORC1 promotes protein synthesis and lipid biogenesis, it controls mitochondrial metabolism and biogenesis; it also inhibits catabolism by blocking autophagy and it inhibits growth factor signaling by activating negative feedback loops that block the PI3K pathway [1820] . The second complex, mTORC2, is composed of six components: mTOR, Rictor, GβL, Sin1, PRR5/Protor-1, and DEPTOR. mTORC2 regulates cellular survival, cytoskeletal organization and metabolism. Compared to mTORC1, the mechanisms of mTORC2 are less understood: It is insensitive to acute treatment with rapamycin, but it was reported that a longterm treatment with rapamycin reduces mTORC2 signaling, suppressing the assembly of the complex [19, 21] . This complex is activated by growth factors with a PI3Kdependent mechanism and the work of Zinzalla et al [22] suggested a possible role of ribosomes for mTORC2 complex activation [20, 22] . Due to its key role in regulating cell growth, survival and metabolism, the mTOR pathway is aberrantly activated in many diseases, including cancer, cardio vascular disease and diabetes [20] . In up to 50% of HCC cases, an aberrant activation of mTOR was reported, mainly downstream of the insulin growth factor (IGF) or epidermal growth factor (EGF) signaling cascades [23] . Many studies showed tumor suppressor miRNAs, the downregulation of which lead to the mTOR pathway activation in HCC cells. [24] showed that the restoration of miR7583p in HCC cell line could suppress cell proliferation, migration, and invasion. miR7583p markedly downregulates the expression of MDM2 and mTOR and, at the same time, the expression of p53, AKT and PRAS40 resulted upregulated. mTOR can be regulated by its upstream effector AKT, which can suppress PRAS40 so as to eliminate the inhibition it exerts on mTORC1 [24] . [25] demonstrated that miR142 expression was reduced in 50 tumor tissues in comparison to correspondent normal tissues and in two HCC cell lines compared to human normal liver cell line. This lower expression was linked to poor clinical parameters like high TNM stage and distant metastasis. miR-142 was identified to directly target the transforming growth factor β (TGFβ), which controls cell vitality, proliferation, epithelialmesenchymal transition (EMT) and neoangiogenesis. mTOR is one of the effector pathways of TGFβ signaling. These findings imply that miR142 is a tumour suppressor gene in HCC and that it increases the TGFβinduced development of hepatocellular carcinoma [25] . [26] .
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miR-187, miR-497, miR-99a, miR-592: IGF 1R activation, through the PI3K/Akt/mTOR axis, is responsible for cell proliferation, migration and invasion in HCC [27] . IGF1R is a target of miR187, miR497, miR99a and miR592 [2830] . miR187 was found downregulated in HCC tissues and cell lines: as reported by Han et al [29] , the restoration of miR187 leads to a significant arrest of HCC growth. miR-497 and miR-99a target the 3′-UTR of both IGF1R and mTOR and were shown to be down regulated in HCC human tissues and cell lines: the co transfection with both miRNAs slowed cell proliferation and the tumor growth in HCC cell lines and in xenograft models [28] . Wang and colleagues demonstrated that miR-592 was significantly downregulated in HCC tissues and cell lines and that its low expression was associated with lymph node metastases [30] . These results indicated that miR187, miR497, miR99a, miR592 could be investigated as potential therapeutic targets for HCC in the future. miR-296-5p: The low expression of miR2965p is directly linked to the activation of the mTOR pathway in HCC growth. Gainoffunction experiments demonstrated that miR2965p inhibited HCC cell proliferation, migration and invasion in vitro, by targeting AKT2. These findings indicated that the miR-296-5p/AKT2 axis plays important roles in HCC carcinogenesis and progression, and that miR-296-5p/AKT2 could be considered a potential target for HCC therapy [31] . miR-139-5p: PDK1/AKT/mTOR axis activation could lead to hepatocellular carcinoma cell proliferation. PDK1 is a known target of miR1395p, found downregulated in HCC tissues and cell lines. Mo et al [32] also observed that miR139-5p/PDK1 expression was regulated by longcoding RNA XIST, which was found overexpressed in HCC.
miR-15b-5p: Opa interacting protein 5 (OIP5) was found upregulated in HCC, inducing tumor growth and metastasis in vitro and in vivo. OIP5 induces mTORC1 and GSK3β/βcatenin signaling activation, through AKT. miR15b5p was found downregulated in HCC cells and OIP5 was found to be its direct target. These findings suggest that the restoration of miR15b5p could inhibit invasion of HCC cells by targeting PTEN, the reduction of which activates the PI3K/Akt pathway [39] . Another miRNA was found to be overexpressed in HCC and plays an oncogenic role in HCC by targeting PTEN: miR 1555p promotes cell growth, migration and invasion, but inhibits apoptosis in vitro and promoted HCC progression in vivo [40] . PTEN is a known target also of miR25, which is overexpressed in HCC cell lines and in liver cancer stem cells (LCSCs) [41] .
Wnt signaling pathway
βcatenin phosphorylation and degradation and its regulation by Wnt are the essence of the Wnt pathway. Signaling by the Wnt family proteins is one of the fundamental mechanisms that induce cell proliferation, cell polarity and cell fate during development and tissue homeostasis (Logan and Nusse, 2004). Canonical Wnt signaling functions by regulating the amount of βcatenin. In the absence of Wnt, cytoplasmic βcatenin protein is degraded by the Axin complex. This non stop degradation prevents βcatenin from reaching the nucleus, and Wnt target genes are thereby repressed [4244] . Inhibitors of Wnt signaling might be effective in HCC, where mutations in the Wnt pathway components are quite common. In the HepG2 cell line, knockdown of βcatenin, mediated by RNA interference, decreased proliferation and growth in vitro [45, 46] (Figure 1 ).
miRNA-10a, miR-30e, miR-215, miR-125b and miR-148a: Ashmawy and colleagues observed that 11 miRNAs (miR10a, miR106b, miR99a, miR148a, miR125b, miR30e, miR199a, miR199a3p, miR24, miR122 and miR215) were downregulated in HCC patients. Five of these miRNAs (miRNA10a, miR 30e, miR215, miR125b and miR148a) were also associated with the expression of genes involved in the Wnt/βcatenin pathway, such as βcatenin, APC and cmyc [47] .
miR-155 and miR-183:
In the same study, the authors detected that miR155 and miR183 were up regulated in HCC patients if compared to controls and that miR155 was correlated with liver cirrhosis [47] .
miR-18a:
Other than miR155 and miR183, other miRNAs involved in the Wnt/b-catenin pathway were observed upregulated in HCC. Liu et al [48] identified that miR18a expression was upregulated in human HCC if compared to the adjacent nontumoral liver tissue. This upregulation promotes the proliferation and migration of HCC cell lines by inhibiting KLF4, a factor that negatively regulates βcatenin expression. This data led the authors to hypothesize that miR18 could be a therapeutic target for HCC treatment [48] .
miR-195:
Yan and colleagues showed a potential application of miR195 in the cancer therapy of HCC. They observed that miR195 was markedly down OIP5mediated oncogenic signaling in HCC [33] . miR-345: Yu and colleagues found that the expression of miR-345 was significantly down-regulated in 65 HCC cases, and matching tumoradjacent tissues, and in HCC cell lines. They also reported a clinical correlation between the low expression of miR345 and venous infiltration, multiple lymph node metastases, and advanced TNM stage. The restoration of miR345 inhibited migration and invasion ability of HCC cells. It was demonstrated that interferon regulatory factor 1 (IRF1) was a direct target of miR345 and that IRF1 mediated the oncogenic effects triggering mTOR/STAT3/AKT signaling [34] . miR-223: Dong and colleagues showed that miR223 was able to suppress cell growth and to promote apoptosis in HCC cell lines (HepG2 and Bel7402). Ras related protein Rab1(Rab1) is specifically regulated by miR223. These data suggested that, in HCC cells, the antitumor effects due to miR223 restoration may be due to the inactivation of the mTOR pathway, caused by the suppression of Rab1 when miR223 is overexpressed. According to these results, miR223 may be a potential therapeutic target for treating HCC, mediating mTOR signaling silencing [35] . Other studies showed oncogenic miRNAs, the upregulation of which leads to the mTOR pathway activation in HCC cells.
miR-33a:
The levels of miR33a were observed as significantly higher in HCC tissues than in adjacent nontumor tissues. This elevated expression of miR 33a correlated with adverse clinical features and poor prognosis. It was demonstrated that miR33a could promote cell growth by modulating the proliferation and apoptosis of HCC cells. Its direct target is PPARα, one of the targets of mTORC1 [36] . miR-302d: Chen and colleagues demonstrated that the overexpression of miR302d promoted cell growth and migration and suppressed apoptosis in HCC cell lines and that it promotes xenograft tumor growth in vivo. These mechanisms were found to be mediated by TGFbR2signaling, a target of miR302d [37] . miR-23b: miR23b was found to be significantly up regulated in tumor tissues of HCC patients. It was demonstrated that this miRNA regulated ST7L, a suppressor of the AKT/GSK3β/βcatenin pathway in HCC cells. MiR23b thus acts as an oncomir in HCC, stimulating proliferation and metastasis through the mTOR and βcatenin signaling cascades [38] . miR-181a, miR-155-5p, miR-25: miR181a was found to be upregulated in HCC tissues compared to adjacent tissues; moreover, its levels were dramatically higher in metastatic HCC tissues than in nonmetastatic HCC tissues. miR181a regulates the proliferation and regulated both in HCC cell lines and in 36 HCCs compared to adjacent nontumoral liver tissues. The expression of miR195 was inversely correlated with AEG1 expression, which was demonstrated to be a target of miR195. Overexpression of AEG1 activates the PI3K/Akt, nuclear factor-κB, and Wnt/βcatenin signaling pathways stimulating proliferation, metastasis, angiogenesis and chemoresistance [49] . An analysis performed using miR195 mimics showed how miR195 inhibited liver cancer cell growth and induced apoptosis in HCC cell lines. The overexpression of miR195 also decreased tumor growth of hepatoma xenografts in nude mice [50] . miR-320a: miR320a was observed to be down regulated in HCC tissues if compared to paired adjacent nontumoral liver tissues. In samples with miR320a inhibition, an upregulation of the expression levels of βcatenin, cmyc, cyclin D1 and DKK1 was observed.
According to this data miR320a may be considered as a tumorsuppressive microRNA in human HCC, through the downregulation of the βcatenin pathway [51] .
miR320a was observed to be downregulated also in a cohort of 50 HCC tissues by Xie and colleagues. The authors also identified c-Myc as a direct target of miR320a and observed that inducing upregulation of miR 320a in HCC leads to inhibition of HCC cell proliferation and invasion capability through cMyc silencing. These data support the role of miR320a as a tumor suppressive microRNA in HCC and provide evidence that miR320a may be used as a potential target for HCC treatment [52] .
miR-98-5p:
Another miRNA observed to be down regulated in HCC tissues is miR985p. Downregulation of miR985p correlates with tumor size, lymph node metastasis, and clinical stage. In addition, HCC patients with low expression of miR985p had a shorter survival time compared to those with high miR985p levels. miR985p downregulation in HCC has been associated with upregulation of Insulinlike growth factor 2 mRNA binding protein 1 (IGF2BP1) in HCC, which induces cell proliferation while inhibiting cell apoptosis [53] .
miR-15b-5p: As reported above (see mTOR pathway paragraph), miR-15b-5p is involved in AKT/mTOR pathway. However, its expression also inhibits GSK3β/ βcatenin signaling in HCC [33] .
miR-1247-5p: miR12475p levels are downregulated in patients with HCC and in HCC cell lines. This downregulation is probably due to hypermethylation Wnt3 is a target of miR12475p and overexpression of miR12475p significantly downregulated its expression. The evidence that the expression of miR 12475p can be regulated by methylation indicates that miR12475p may be a potential therapeutic target for HCC [54] .
JAK-STAT pathway
The JAK/STAT pathway regulates development and it is involved in stem cell maintenance, hematopoiesis and inflammatory response. Active JAKs recruit STAT (signal transducers and activators of transcription) proteins that form dimers that translocate to the nucleus when phosphorylated. These dimers modulate transcription of genes involved in differentiation, proliferation and apoptosis. The JAK/STAT pathway is regulated at multiple levels. Many cancers and neoplastic cells employ several strategies to activate the JAK/STAT pathway (e.g., activating mutations in STATs or reduced expression of negative regulators [5557] ) (Figure 2 ).
miR-214-3p: miR2143p is expressed at low levels in HCC [58] . PIM-1 is an oncogene encoding for a serine/ threonine kinase protein involved in several human cancers. PIM1 transcription is initiated by STAT proteins and plays a key role in signal transduction, contributing to both cell proliferation and survival, and thus providing an advantage in tumorigenesis [59] . PIM1 is a miR214 3p target and PIM1 expression is enhanced in HCC [58] . miR-30e: miR30e is downregulated in the majority of HCC tissues. Restoration of its expression down regulates JAK1 expression levels. Silencing JAK1 inhibits migration, proliferation and invasion of HCC cells. For this reason, miR30e might be a prognostic marker of HCC and a putative therapeutic target [60] . miR-340: JAK-1 was also identified as a direct target of miR-340. miR-340 was found to be significantly downregulated in HCC tissues and cell lines and, in vitro, its overexpression inhibited migration, cell proliferation and invasion [61] . miR-140-5p and miR-200: miR1405p and miR200 were downregulated in HCC and predicted to target Pin1 [62] . Pin1 is an independent factor for poor prognosis in HCC, it is overexpressed in ~70% of human HCCs [63] , and it is correlated with larger tumor size, higher incidence of MVI and poor prognosis in HCC [64] . The overexpression of miR1405p inhibits human HCC cell growth, colony formation and migration [62] . miR-638: miR638 expression in HCC tissues is down regulated if compared to the paired nontumoral tissues. Low expression of miR638 was linked to venous infiltration and TNM stage. Moreover, low levels of miR638 are associated with a lower Ecadherin and vimentin expression if compared to cells showing high miR638 levels. miR638 downregulation increases SOX2 expression, a gene overexpressed in HCC and involved in oncogenesis and in the progression of various cancers [65, 66] . Moreover, SOX2 expression is associated with overall poor survival in HCC patients and it promotes cancer cell invasion [67] . These data lead to considering miR638SOX2 as a putative target for repressing the development and metastasis of HCC [68] .
Apoptosis
Apoptosis occurs normally during development to maintain cell populations in tissues and as a defense mechanism in immune reactions or when cells are damaged [69, 70] . TP53 was the first tumor suppressor gene to be linked to apoptosis and it is well established that TP53 mutations occur in the vast majority of human cancers [71] . In fact, if on one hand wild type p53 promotes apoptosis, cellcycle arrest and senescence, the loss of p53 function increases viability, chromosomal instability and cellular lifespan. Disruption of the apoptotic pathway correlates with the progression of several tumors [72] .
miR-30a:
Anoikis is a form of cell death due to loss of contact of the cells with the extracellular matrix. Low levels of miR30a were observed in several HCC cell lines (Hep3B, HepG2, SMMC7721, MHCC97L, MHCC97H and HCCLM3) and in HCC tumor tissue compared to adjacent nonneoplastic tissue. miR 30a silencing is accompanied by an increase in the expression of Beclin 1 and Atg5 proteins and by a decreased number of cells undergoing anoikis [73] . miR-365: miR-365 expression was significantly lower in HCC cells (SMC7721, HepG2, Bel7404 and Bel7402) compared to a normal hepatocellular cell line (LO2). Inducing up-regulation of miR-365 leads to a significant decrease in cellular activity and to the inhibition of tumor growth. It has also been observed that in cells with an upregulation of miR365, the expression of Bax, cyto C and cleaved caspase 3, which is downstream of Bcl2, were also markedly upregulated [74] . miR-526a: miR526a is downregulated in HCC tissues. In vitro, the introduction of miR526a into HCC cell lines significantly decreased HCC proliferation, migration and invasion, via p21 inactivation [75] . miR-377: miR377 was downregulated in HCC tumors if compared to the adjacent nonneoplastic tissue. In vitro experiments with HCC cell lines demonstrated that a gain of miR377 function inhibited colony formation, suggesting that miR377 plays a key role as a tumor suppressor in HCC. In cells with high levels of miR377 the apoptotic rate was significantly higher than in the controls. BclxL is an antiapoptotic protein and it is overexpressed in about 33% of HCC [76] , conferring resistance to apoptosis. The higher level of apoptotic rate observed in cell lines with miR377 overexpression was associated with a concomitant downregulation of BclxL mRNA levels, suggesting that BclxL is a target of miR377 [77] . miR-199a-5p: miR199a5p was downregulated in HCC tissues compared to pairmatched nonneoplastic hepatic tissues [78] , and the same was the case for let 7c expression [79] . miR199a5p downregulation was correlated with tumor size and invasion. Moreover, the low expression of miR199a5p and let7c was associated with higher metastatic capability in HCC cell lines. MAP4K3 is a proapoptotic kinase that activates the Intrinsic Apoptosis Pathway [80] . MAP4K3 gene was predicted as a possible target of miR199a5p and let 7c and the upregulation of both miRNAs leads to a significant decrease in MAP4K3 protein level, resulting also in a decrease in HCC cell migration and invasion [78] . miR-330: miR330 level was higher in HCC tissues if compared to adjacent nonneoplastic specimens. The upregulation of miR330 was associated with shorter survival in HCC patients. ING genes have been reported to be implicated in apoptosis, cell cycle regulation, and DNA repair. ING4 plays important roles in many cancerrelated processes, such as apoptosis, cell proliferation and growth, angiogenesis and migration. ING4 expression is decreased in several cancers [81] . Overexpression of miR330 reduced the expression of ING4 in HCC cells promoting HCC cell proliferation and invasion [82] .
MAPK cascade
The mitogenactivated protein kinase (MAPK) pathway is characterized by different kinase proteins that link extracellular signals to the machinery that controls physiological cellular processes such as growth, differentiation, proliferation, migration and apoptosis. Alterations in the MAPK cascade impinge on almost all previously listed physiological processes and play a critical role in the development and progression of cancer [83] (Figure 3 ). miR-346: miR346 was downregulated in HCC tissues and its expression levels are associated with tumor size and TNM stage. An in vitro study revealed that the loss of miR346 leads to the upregulation of S phase in HCC cell lines. One of the putative targets of miR346 is SMYD3. SMYD3 is an oncogene upregulated in several tumors, including HCC [84] . SMYD3 expression leads to methylation of MAP3K2 by increasing MAP kinase signaling and promoting the formation of Rasdriven carcinomas [85] . Restoring miR346 levels in HCC cell lines prevented proliferation through the suppression of SMYD3 expression [86] . miR-143: miR143 expression was reduced in HCC tumor tissues and human liver cancer cell lines (SMMC7721, Hep3B, HepG2, Huh7, Bel7402, MHCC97H and SKHep1) compared to nonneoplastic adjacent tissues and normal liver cell line (L02), respectively [87] . GATAbinding factor 6 (GATA6) is a transcriptional factor with an oncogenic role in various types of tumor, favoring cancer progression [88] . GATA6 is a potential target for miR143 and its expression is downregulated by miR143 overexpression in HepG2 and Bel7402 cells [87] . miR-125a: miR125a was detected as downregulated in 80% of HCC biopsies if compared with the adjacent nontumor liver tissue. When grouping patients according to HCC etiology, miR125a was downregulated in 80% of HBV patients, 78% of HCV patients, and in all 4 patients with nonalcoholic steatohepatitis. In vitro analysis revealed that MMP11, SIRT7 and cRaf were the main miR125a targets. In support of this, MMP11, SIRT7 and cRaf were upregulated in about 80% patients with miR 125a downregulation, hinting at an oncosuppressor effect of the microRNA through the regulation of MMP11, cRaf and SIRT7 expression [89] . miR-217: miR217 expression levels in HCC tissues were significantly decreased, while MTDH levels were significantly upregulated. miR-217 up-regulation in HCC cell lines lead to a remarkable downregulation of MTDH mRNA expression, demonstrating that MTDH is a target of miR217. Metadherin (MTDH) is a transmembrane protein overexpressed in several cancers [90] and it is associated with tumor development and with aggressive course [49] . In cell lines with miR217 upregulation and MTDH downregulation, cell apoptosis notably increased, indicating that miRNA expression promotes apoptosis of HCC cells [91] . miR-200a: miR200a was downregulated in HCC cell lines and tissues and it was correlated with the metastatic ability of HCC [92] . GAB1 is one of the molecules targeted by miR200a. The overexpression of miR200a suppressed the levels of GAB1 in HCC cell lines, inhibiting cell migration and invasion [92] .
TIssUE miRNA AND POsT-sURGICAL OUTCOmE
Liver resection
In a widearray miRNA analysis on resected patients with lowstage HCC (within the Milan criteria), Sato et al [93] found that the deregulation of 13 intratumoral miRNAs (miR100, miR99a, miR99b, miR125b, miR378, miR1295p, , miR125a5p, miR497, miR22, miR1403p, miR145, miR221, miR195) significantly correlated with post-surgical ( Table 1 ). The same is applies to the deregulation of more than 50 miRNAs in the nontumoral tissue, among which the most significant was miR-96. miR-125b downregulation, in combination with more typical prognostic factors, was also correlated with low diseasefree survival (DFS) after resection in later works [94] (Table 1) .
In a more recent study on resected HCC, Lin et al [3] identified 16 miRNAs related to MVI, the hierarchical clustering of which was able to predict survival after resection: miR4525p, miR378, miR95p, miR550a 5p, miR15a5p, miR1405p, let7g, miR1523p, miR 1225p, miR2123p, miR23b, miR365a, miR6295p, miR1270, miR6593p and miR3941 (Table 1) . Other miRNAs whose downregulation was correlated with poor prognosis after resection were miR3423p [95] , miR6553p [96] , miR1051 via NCOA1 deregulation [97] , miR223 associated with an increased Stathmin1 expression [98] , and miR4833p in "histologically advanced" HCC (high-grade and/or MVI) [99] . Upregulation of miR19b was correlated with good prognosis after resection in resected patients with advanced HCC [100] . Albeit miRNA downregulation is often associated to worse prognosis, upregulation is not always a good prognostic sign: for example, the upregulation of miR135a, miR29a5p and miR221 was significantly associated with early HCC recurrence [101103] (Table 1) .
Liver transplantation
The search for molecular predictors for HCC recurrence after orthotopic liver transplantation (OLT) is even more tangled than after resection, due to the particular immune status of the recipients and the intrinsic capability of HCC tumor cells not only to give metastases to distant organs, but also to implant in the graft. A wide microarray profiling by Barry et al [104] found more than 60 miRNAs to be deregulated in recurrent HCC after OLT. Interestingly, miR125b and miR497 already mentioned above in postresection recurrence are among the most significant [93, 104] . Common mechanisms beyond HCC recurrence after both resection and liver transplantation are likely to indicate that a more aggressive tumor biology leads to a higher risk of recurrence or dissemination.
Morita et al [105] demonstrated that the concomitant upregulation of miR18a and downregulation of miR 199a5p correlated with the worst diseasefree survival in a population of 70 transplanted patients. The most represented sites of recurrence were lymph nodes, lung and bone. The mechanisms proposed by the authors included the link between miR-18a and TNFα, as well as the regulation of the HIF1α, the VEGF-A, and the IGF pathways by miR199a5p [105] (Table 1) .
Response to chemotherapy
The role of miRNAs in the response to chemotherapy is still largely unresolved, especially for HCCs, which are malignancies with an extreme molecular heterogeneity. Due to this heterogeneity, no target therapies specific for HCC have been available since the introduction of Sorafenib in 2005. Sorafenib changed the natural history of patients with advanced HCC not suitable for surgery [7] , but no molecular markers for the prediction of the response to this therapy are available yet. Only few in vitro studies focusing on the role of miRNAs in the response to Sorafenib exist, e.g., miR137 [106] and miR125a5p [107] . A very interesting recent study found that the deregulation of miR181a5p in patients' serum was correlated with a worst disease control after Sorafenib therapy [108] (Table 1) .
As for the resistance to classic chemotherapic drugs, other in vitro studies showed that miR205 5p and miR503 were involved in the resistance to 5Fuorouracil [109, 110] , miR33a5p was involved in the resistance to Cisplatin [111] , and miR31 was involved in the resistance to Adriamycin [112] . An exhaustive in vitro and in vivo study by Jin et al [113] showed that the tissue levels of miR-26a/b regulated the mechanism of autophagy, thus influencing the cell's resistance to drugs. So, in spite of the many contributions in the literature about miRNAs and HCC, there is a lack of in vivo studies on the issue of the response to systemic therapy.
sERUm mIRNAs
The analysis of miRNAs in serum and other body fluids (i.e., urines) would be crucial for clinical management, since it would allow diagnosis and/or prognosis of HCC patients before surgery. However, the study of serum miRNAs is still a complicated issue, due to the high tumor/patient variability and the lack of a standard control among laboratories. miR122 the miRNA most represented quantitatively in the human liver is the most promising in early HCC diagnosis, albeit all authors generally agree that miR122 serum levels also increase in nonneoplastic liver diseases [114] . The first proposed serum panel for HCC detection was miR122 associated with miR21 and miR223 [115] . A recent metaanalysis by Ding et al [116] showed that difficulties exist also in the comparison of scientific results among centers: the "highfrequency expression miRNAs" best suited for HCC diagnosis from serum were miR122, miR21, and miR199, and generally a panel of multiple serum miRNAs is advisable. For example, a panel composed by three serum miRNAs (miR923p, miR31265p and miR107) together with serum alphafetoprotein (AFP) showed higher sensitivity and specificity in the early diagnosis of HCC compared to AFP alone [117] . Another study found that serum miR939, miR595, miR519d, and miR494 were able to differentiate cirrhotic patients with and without HCC better than AFP [118] . Other serum miRNAs are likely to be useful in the diagnosis of local or distant HCC recurrence after surgery, like miR486 5p [119] and miR34a [120] .
CONCLUsION
The extreme heterogeneity of HCC, in both its morphological picture (as assessed by radiologists and pathologists) and in its clinical course and outcome, reflects the heterogeneity of its biomolecular status. Several molecular pathways are involved in hepatocarcinogenesis, as well as in the regenerative dysplasticneoplastic progression observed in cirrhotic nodules. As a consequence, the up or downregulation of several miRNAs is involved. As evidenced by the present review, the most represented miRNAregulated pathway in HCC is mTOR, but other pathways, such as as apoptosis, Wnt or MAPK, are also influenced by miRNA expression levels. Moreover, as shown in Table  1 , some miRNAs involved in at least one of the main molecular pathways of hepatocarcinogenesis are likely to have a clinical significance (recurrence after surgery, response to systemic therapy). The identification of specific tissue and serum miRNAs, able to predict the arising of HCC in cirrhosis, to predict HCC recurrence after surgery, or to predict the response to systemic therapy, might lead to a drastic improvement in the management of these patients. Anyhow, the clinical application of miRNAs has always been complicated, especially because of interlaboratory variability, due to the choice of control to be used for normalization. A recent study of our group showed how the miRNA profile of HCCs changed using a pool of cirrhotic tissues or a pool of healthy livers as nontumor controls [121] . Other authors suggested to employ stable miRNAs as controls for the study of the expression of other miRNAs [122] . In the light of the available data, it would be useful to elaborate, based on the most representative miRNA in in vivo model (e.g., rat, mouse), to better understand the possible role of these molecules as theragnostic markers in HCC. The issue is still open, and the standardization of miRNA analysis among laboratories is crucial for the development of a miRNAbased diagnosis of liver nodules, as well as of a miRNAregulatory therapy.
